Latest news with #Telo
Yahoo
24-07-2025
- Business
- Yahoo
International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting
Toronto, Ontario--(Newsfile Corp. - July 24, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the International Myeloma Society ("IMS") has accepted Telo Genomics' abstract submission for a poster presentation on minimal residual disease ("MRD") during the upcoming 22nd International Myeloma Society Annual Meeting in Toronto, Canada. The new abstract titled, "3D Telomere Profiling of MRD (Minimal Residual Disease) in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression," will be presented at the meeting by Dr. Yulia Shifrin, Laboratory Director of Telo Genomics and published in Clinical Lymphoma, Myeloma & Leukemia. The abstract entails a technical methodology of MRD assessment based on TeloView profiling. Details of the abstract will be provided after the poster session. TeloView MM-MRD's proprietary approach of counting and profiling individual MRD cells has the potential to provide actionable information on risk of relapse to clinicians. The International Myeloma Society (IMS) is a global professional organization dedicated to advancing the science and treatment of multiple myeloma. Its upcoming 22nd Annual Meeting, will take place from September 17-20, 2025. IMS meetings are widely considered as a defining annual forum in the myeloma field. "We are excited to share the next clinical application of our 3D telomere application for MRD for multiple myeloma at IMS," said Dr. Sabine Mai, Telo's Co-Founder. "The acceptance is a result of our commitment to develop a clinical offering and a novel approach of liquid biopsy MRD." The Company announces that, further to its news release dated February 27, 2025, the Company has issued an aggregate of 411,539 common shares ("Shares") to Trusted Health Advisors LLC ("THA"), to compensate THA for its provision of services related to the partnering and commercialization of Telo's diagnostic technologies from January to July 1, 2025. Pursuant to the agreement between THA and the Company, 214,605 Shares were issued at a deemed price of $0.12 per Share, and 196,934 Shares were issued at a deemed price of $0.125 per Share, for total consideration of approximately $50,369, or US$36,000. All Shares are subject to a four-month hold period expiring November 11, 2025, in accordance with applicable securities law and TSX-V policies. In addition, the Shares issued at $0.12 per Share are subject to a voluntary resale restriction expiring March 31, 2026, and the Shares issued at $0.125 per Share are subject to a voluntary resale restriction expiring June 30, 2026. About MRD Assessment Minimal Residual Disease ("MRD") is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells, between being in remission or active, provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals in multiple myeloma. MRD testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023). About Multiple Myeloma Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US. About Telo Genomics Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit For further information, please contact:Guido BaechlerExecutive Chairman647-477-9365info@ Centre, South Tower101 College Street, Suite 200Toronto, ON, M5G Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. To view the source version of this press release, please visit
Yahoo
15-05-2025
- Business
- Yahoo
European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress
Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the European Hematology Association ("EHA") has accepted Telo Genomics' abstract submission for a poster presentation during the upcoming EHA 2025 Congress. The new abstract is titled "Advanced Risk Prediction for Smoldering Multiple Myeloma ("SMM") Patients Through the Combination of Mayo Clinic's 2/20/20 Model with TeloViewSMM Risk Assessment." It reports a synergistic outcome from the co-application of the 2 assessments, for determining the risk of progression from SMM to active multiple myeloma. For the 88 patients examined, the predictive accuracies corresponding to Receiver Operating Characteristic ("ROC") curves were 0.64 for 2/20/20, 0.77 for TeloViewSMM and 0.80 when applied together. The abstract will be presented on June 14th by Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic, Telo's collaborator and Lead Clinical Investigator on the TeloViewSMM validation studies. Dr. Kumar has played a pivotal role in developing the 2/20/20 risk stratification model, which is currently included in the smoldering myeloma prognostic international guidelines. "We are pleased to be presenting our abstract at EHA. The 2/20/20 risk model has found broad implementation in the clinic, and it has been further refined by inclusion of cytogenetic abnormalities with fluorescence in situ hybridization (FISH) testing," said Dr. Sabine Mai, Telo's Co-Founder. "Since TeloViewSMM could also be added to existing FISH laboratory workflows, the co-use of these assessments is now appearing both highly scalable and clinically advantageous." About TeloView-SMM The TeloViewSMM test is for SMM, a precursor to multiple myeloma. The test stratifies patients flagged with the elevated M-protein biomarker, between patients that are high-risk to progress to the full stage of the myeloma disease, and those that are low-risk patients, and confirms the stability of disease in these patients. To date, this has been a critical unmet need in the management of SMM patients. High risk SMM patients may benefit from immediate treatment intervention, with the possibility of a cure, due to recent advancement in treatment regimens. Alternatively, low risk patients can be monitored using TeloViewSMM, without exposing these patients to unnecessary and debilitating treatment. Critically, TeloViewSMM can be used periodically as a non-invasive liquid biopsy test that can be performed using a simple blood sample. About Multiple Myeloma Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US. About Telo Genomics Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit For further information, please contact:Guido BaechlerExecutive Chairman 416-673-8487 info@ MaRS Centre, South Tower101 College Street, Suite 200Toronto, ON, M5G 1L7 Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. To view the source version of this press release, please visit
Yahoo
10-04-2025
- Business
- Yahoo
Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025
Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genomics' abstract submission regarding a concordance analysis between blood and marrow samples, using the TeloView® Minimal Residual Disease (MRD) methodology, as an online publication at the ASCO Annual Meeting. MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. Telo's ongoing MRD clinical trials with McGill University/Jewish General Hospital have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include: i) identify and quantify the number of MRD cells circulating in the patient's blood post marrow transplantation; and ii) profile the isolated circulating MRD cells using Telo's proprietary technology TeloView®, to assess disease aggressiveness in each individual MRD cell. The two MRD tests are designed to be liquid biopsy-based, which is at the forefront of precision medicine. ASCO's 2025 Annual Meeting will take place May 30 - June 3, 2025, in Chicago, Illinois. Founded in 1964, ASCO brings together more than 45,000 oncology professionals worldwide, dedicated to improving cancer care through research, education, and promotion of the highest quality patient care. ASCO is widely considered one of the most prestigious oncology research conferences of the year. "We are really pleased to have our abstract accepted by ASCO, it indicates the novelty and importance of our TeloView® based MRD applications and the impact we hope to have on patients and physicians as they manage MM patients post-transplantation," said Sabine Mai, Telo's co-Founder. About MRD Assessment Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023). About Multiple Myeloma Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US. About Telo Genomics Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit For further information, please contact:Guido BaechlerExecutive Chairman 416-673-8487 info@ MaRS Centre, South Tower101 College Street, Suite 200Toronto, ON, M5G 1L7 Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. To view the source version of this press release, please visit
Fox News
24-03-2025
- Automotive
- Fox News
America's smallest EV truck prototype has arrived
California-based EV startup Telo Trucks has unveiled the preproduction prototype of its MT1 electric mini-truck, signaling a significant step toward production. At an event in Los Angeles, attendees got an up-close look at the MT1, which combines the utility of a full-size truck with the compact footprint of a Mini Cooper SE. This innovative design challenges the oversized vehicle trend dominating the U.S. market by offering a practical and efficient alternative for urban and outdoor enthusiasts alike. The MT1 is designed to pack Toyota Tacoma-like functionality into a vehicle just 152 inches long, roughly the size of a Mini Cooper SE. Despite its small stature, it boasts impressive interior space for five adults and a 60-inch truck bed. The truck's folding midgate allows it to carry items as large as an 8-foot surfboard or 4-by-8 plywood sheets, making it ideal for both city errands and weekend adventures. Telo offers two configurations for the MT1. Both models feature fast-charging capabilities, allowing for a 20%-80% recharge in just 20 minutes. Optional solar panels on the cab roof, tonneau cover or camper shell can add up to 15 miles of range per day, further enhancing its efficiency. The MT1 incorporates several standout features. The MT1 will start at $41,520 for the base model, with upgrades available for additional power and range. While full-scale production is still a couple of years away, Telo is actively testing its prototypes for safety and durability ahead of homologation inspections next winter. The prototypes will be hand-built by leading California-based manufacturer Aria Group, which is a major player in the early stage development of concept vehicles and rapid prototyping for the most notable automotive companies globally. Telo has already secured more than 5,000 preorders, translating to more than $250 million in customer commitments, a remarkable achievement for a startup challenging conventional truck design. The Telo MT1 is no doubt an intriguing concept that definitely challenges the oversized truck norm with its compact size and impressive capabilities. With preproduction prototypes now unveiled and testing underway, Telo seems to be making some real progress. However, it remains to be seen if Telo can deliver on its promises, especially in terms of production and affordability. While the MT1 has the potential to carve out a niche in the EV market, it seems like there are a lot of hurdles that undoubtedly lie ahead before we see this on the streets in the future. Would you ever consider downsizing to an MT1 mini-truck? Why or why not? Let us know by writing us at For more of my tech tips and security alerts, subscribe to my free CyberGuy Report Newsletter by heading to Alert: Malware steals bank cards and passwords from millions of devices. Follow Kurt on his social channels: Answers to the most-asked CyberGuy questions: New from Kurt: Copyright 2025 All rights reserved.
Yahoo
11-03-2025
- Automotive
- Yahoo
Unbelievably tiny truck has a head-turning design — and a seriously powerful new feature
One of the world's tiniest electric trucks is about to be even more powerful and eco-friendly, thanks to a new solar-powered upgrade. Telo announced in January that it has plans to offer three solar panel kits for its tiny MT1 electric pickup trucks. The kits include solar panels on the rooftop that integrate with the cab, a solar camper shell, and a solar truck tonneau cover. The solar panels, which solar car company Aptera will supply, can generate up to 200 watts at peak sunlight. Telo says this gives the truck an additional 1-2 kWh of battery charge per day. The company aims to create the world's most efficient electric truck with the MT1, and this new solar panel integration upgrade can help make it an even more efficient alternative to gas cars. Would you want EV-charging roads installed in your town? Sign me up Depends how much it costs No way I'm not sure Click your choice to see results and speak your mind. While electric vehicles are becoming popular alternatives to gas-powered vehicles, many drivers are still hesitant to make the switch. This is due to several factors, including range anxiety, charging accessibility, and sustainability concerns due to the environmental costs of building EVs and manufacturing their batteries. The MT1's integrated solar panels help mitigate range anxiety and charging limitations by providing a continuous renewable power source. The solar panels extend battery life, reduce reliance on charging stations, and provide a renewable energy resource, which can help ease range anxiety. One of the most common concerns about EVs is the environmental impact of mining for battery materials. However, according to University of Oxford researcher Hannah Ritchie, clean energy materials like lithium, cobalt, and copper require significantly less mining compared to fossil fuels. The world currently mines about 16.5 billion tons of fossil fuels annually — more than 2,000% of the materials needed for clean energy, which is about 7.7 million tons. And, unlike oil and coal, these clean energy materials can be recycled, making EVs a more sustainable long-term solution. Given Ritchie's findings on the environmental costs of clean energy minerals versus fossil fuels, switching to low-carbon technology like EVs seems like a viable alternative to gas cars. Beyond the environmental benefits, EVs can help cut routine maintenance and fuel costs and eliminate tailpipe emissions. And with the Telo MT1 getting solar panel integration, the electric truck can have an additional energy resource. The MT1 is now available for pre-order for just $152, with solar panel kits expected to be available for separate pre-orders later this year. Telo announced that a prototype truck is currently in development but hasn't disclosed when it will become available. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
